Singapore-Based Digital Health Company Holmusk Raises $9.75 Million

By Dan Anderson ● September 26, 2018

Singapore-based Holmusk is a digital health and data analytics company that has raised $9.75 million in pre-series A financing. Heritas Venture Fund participated in this round along with participation from several undisclosed new and existing investors. Holmusk plans to use the funding to expand in the US and Europe.

What does Holmusk do? Holmusk uses data science to help accelerate research in order to improve outcomes for people who have chronic diseases. Holmusk has partnered with a number of pharmaceutical companies and healthcare providers to build actionable insights for personalized medicine using predictive algorithms. And Holmusk has an innovative digital health platform for driving patient engagement.

“I’m excited that we are entering this next stage of growth. This financing reflects the trust our investors have in us and gives us a healthy financial runway, which allows us to focus on executing and growing aggressively in our core segments of chronic disease management and behavioral health,” said Holmusk founder and CEO Nawal Roy. “The world is faced with unprecedented health challenges and we’re thrilled to play our part in addressing them.”

Holmusk also acquired a behavioral health EHR company called MindLinc, which led to the company having one of the largest behavioral health databases in the world. And now Holmusk is developing MindLinc 2.0, a platform that will “include predictive disease models based on longitudinal patient data.” This platform is being developed by combining system dynamics with deep learning neural networks along with quantitative systems pharmacology.

“Holmusk’s focus on promoting healthy lifestyles and addressing chronic disease management made this an exciting opportunity to be a part of,” added Heritas Capital Management CEO Chik Wai Chiew. “Its approach of combining deep analytics with clinical research and real-world data is promising and we are pleased to see the company on track to build upon the successes of GlycoLeap and SuperLeap and develop next generation versions in 2019.”